The aim if this study is to explore the impact of the various prognostic factors on overall survival in women with ovarian cancer (OC). Patients diagnosed with gynecologic malignancy in Gynecology Clinic of Baskent University Medicine Faculty between 2010 and 2015 included to study. Patients with ovarian (n= 112) cancers examined retrospectively. Kaplan-Meier, Univariate and Multivariate Cox regression model were performed to estimate for associations of potential variables with survival factors. The mean patient age was 56.4 y, range 20-80. The overall survival was 94.3%, 83.4%, 66.4%, 54.7% and 42.8% at 1, 2 3, 4 and 5 years respectively (60.5 months, range 43-68). 3-year disease-free survival was 25.3% (18.3 months, range 17-20). Multivariate analysis of patients indicated that stage, histology, grade, age at diagnosis, comorbidity, recurrence, BMI, menopausal status and regional distance were independent prognostic factors on survival (p< 0.05). In conclusion, these results will presents a framework to identify fundamental causes in survival for OC. 
INTRODUCTION
Ovarian cancer (OC) is the deadliest gynecologic cancer worldwide, with nearly 225.000 new cases diagnosed each year and 140.000 deaths annually.Lifetime risk of OC in women is one in 71, and the risk of dying from the disease is 1 in 95. 1 Based on GLOBOCAN estimates, the incidence and mortality of OC varies in different regions of the world; Scandinavian (14.9/100000), USA (13.3/100000), UK (11.7/100000), Russian Federation (11.3/100000), and Japan (4.8/100000).
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In Turkey (6.6/10000), OC is also a major health problem in women following breast cancer. This is higher than that of the previous reports in Turkey. 3 Regrettably, identifying this disease is difficult. There is no routine, screening test to accurately and reliably detect OC in the general population so diagnosis of OC in the advanced stages leads to this cancer being considered as a fatal disease. Although the incidence and mortality of this disease is high, its prognostic factors are still not completely understood especially in low-income countries. 4, 5 In the literature, survival depends on many factors such as patient's family history, multiple comorbidities, postoperative complications, chemotherapy toxicities, increasing age, postmenopausal period, recurrence, presence of positive lymph nodes, advanced stage and grade, carcinosarcomas subtype, ascites, never having been pregnant and having never taken oral contraceptives, as well as lifestyle factors such as performance status, smoking and obesity. [6] [7] [8] [9] [10] [11] Statistics show that survival from all cancers in women was 64.2% while it was approximately 45.0% for OC globally and the 5-year survival rate has improved in OC by only 9% since 1975 even in high-income countries.
2 A 5-year survival rate is about 43% in Turkey (1970s-37%, 1980s-40%, and 2000s-45%).
3 Despite the recently improvements such as advances in the diagnosis, staging, and treatment of OC, and provided significant advancement of patients survival, major challenges related to the prognostic implications of its clinicpathologic characteristics remain controversial in the management of OC. Most women with OC are likely living with the disease rather than living cancer-free and some oncologists consider OC a chronic disease. 9, 12 Relatively, limited comprehensive national information describing clinical and nonclinical factors associated with survival is available in Turkish women with OC. Therefore, estimating survival is remarkable that provide an understanding of the disease course and better prognosis for OC.
PATIENTS AND METHODS
The aim of this study was to investigate determinant factors associated with survival of women with OC over the course of five years. The population of the study consisted of all patients with OC in years 2010-2015 who were actively followed-up and age 18 years or older were included at the Gynecologic Oncology Clinic, Faculty of Medicine, Baskent University Hospital (n= 112). Patients with unknown treatment data, or missing information were excluded. In addition, patients who survived less than 12 months after diagnosis were excluded to limit bias. Patients were scheduled for follow-up every two months in the first year, every three months during the second year and every six months thereafter. Follow-up data such as date of last visit and disease status at the time of the last contact were also noted. This study was conducted at a multidisciplinary tertiary care center. The research was approved by the University of Baskent Institutional Review Board and was conducted in compliance with principles of Helsinki declaration.
The data were collected by using three different forms between April 2016 and January 2016 through hospital-based cancer registry; 1) The Patient Information Form, 2) The Charlson Comorbidity Index (CCI), and 3) The Eastern Cooperative Oncology Group (ECOG) Performance Scale. 
The Patient Information Form

The Charlson Comorbidity Index (CCI)
Comorbidity was measured for each patient using the Charlson Comorbidity Index (CCI), categorized as 0, 1, or ≥2, with a higher score indicating a larger number or greater severity of comorbidities. 14 The CCI, ranging from 0 to 29, consists of a weighted sum of 17 major illnesses (e.g., myocardial infarction, stroke, diabetes, liver disease, dementia, renal disease). HT was included in the list of possible comorbid illnesses.
European Cooperative Oncology Group (ECOG) Performance Scale
This scale was developed by the Eastern Cooperative Oncology Group (ECOG) in 1982 to classify a patient according to their functional impairment, compare the effectiveness of therapies, and assess the prognosis of a patient (from 0 to 5, with 0 denoting perfect health and 5 death).
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Statistical Analysis
Descriptive statistical analyses were performed with SPSS version 18 (SPSS inc., Chicago, IL). Categorical variables were compared using Pearson chi-square test and continuous variables using the Wilcoxon-Mann-Whitney and Kruskal-Wallis tests. Survival was estimated using the KaplanMeier method. Univariate and multivariate Cox Regression model (95% CIs) were used to evaluate the effects of multiple prognostic factors on survival. 16 The significance level was p< 0.05.
RESULTS
There were 112 patients who met inclusion criteria. The patients' general characteristics are shown in Table 1 . The median age at diagnosis was 56.4 years + 11.3 (min: 20 -max: 80). Findings determined that 56.2% were primary school graduates, 79.7% were housewives, 86.6% were married, 67.9% had their income equal to expenditure, and 86.6% were urban dwellers. The mean parity was 3.35, ranging from 0 to 10. All of the women had health insurance, 73.2% did not smoke (99.5% did not drink alcohol). Distance from residence to center, miles (range) was 210±10.2 (0-750) ( Table  1) .
Seventy percent of women were diagnosed during menopause (the rate of surgically induced menopause was 34.8%). More than half of women were obese (56.3%). The majority of women had a caregiver (85.7%). One in three received psychological support for their illnesses. Thirty-three percent of women had cancer stories in their families and (Table 3) . Hematologic and non-hemato- (Table 6 ).
Compared to good prognosis women, poor prognosis women were less educated, and income level, had before surgery, high toxicity, and re-hospitalization. However, there was no significant difference in OS between the groups (p> 0.05). There were no major differences in distribution of other prognostic factors (p> 0.05).
DISCUSSION
OC is often called the silent killer; women often ignore early signs because there are no clearly identifiable initial symptoms often confused with complaints of common benign gastrointestinal disorders such as abdominal distension and pain due to acidity. Because of diagnostic challenges only one fifth of OC patients are detected at the localized stage. Frequently, women are medically managed for indigestion or other complaints without having a pelvic examination, thus significant delays before diagnosis are very common. 4, 5 In our study abdominal distension was seen in 44.6% of patients, which was followed by abdominal/pelvic pain with a rate of 19.6%, and vaginal bleeding/irregular menstrual cycles was found in 35.7%. In accordance with our study Oge et al 7 also reported abdominal swelling as the most common complaint (59.1%), and the second most frequent complaint was reported as abdominal pain Cancer statistics often use 5-year OS rate to present a better idea of the longer-term outlook for people with cancer. 5 We found that the OS for OC was 94.3%, 66.4%, and 42.8% at 1, 3, and 5 years, respectively. Also, the median OS time was 60.5 months. The slope of decline in OS was reduced during the first years after diagnosis. Most patients diagnosed with OC, survival is theorized to be 100%, who are still alive after 5-years, are presumably living with the disease rather than living disease-free. 5 Our analysis demonstrated that the DFS was 18.3 months (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) . The Surveillance, Epidemiology and End Results-SEER database from 1995 to 2007 with epithelial OC who were actively followed-up and age 20 years or older were included for analyzing OS in the United States (40.692 patients) and OS was 65%, 44%, and 36% at 2, 5, and 10 years, respectively. 10 Bailey et al. . 18 In a study the median DFS and OS for patients with OC were 35.0 months and 54.0 months respectively. 19 In different study done by Anuradha et al in 2014, 1192 Australian women diagnosed with invasive epithelial OC in 2005 were identified through state-based cancer registries and the 5-year OS was 53%. 20 A Swedish study published in 2009 of 682 patients with epithelial OC found a 10-year relative survival rate of 38.4%, the median OS time was 81 months (52-109 months) in OC patients. 6 Larger population-based analyses of 10-year OS in OC have not been published in the Turkish populations. In a study performed in Turkey, according to the surgical stages I, II, III and IV median survival was 78.5 months, 60.1 months, 33.9 months and 16.1 months respectively and significantly different. 7 In a study by Karaca 21 study, a number of 13.590 women (from 9 nationwide cancer registry centers) were evaluated who got gynecological cancer diagnosis (31.2% OC) in Turkey between 2004 and 2011, overall 5-year observed OC survival rate was 46%. Buldanlı et al reported that OS was 51.6% in Western Turkey.
When we compare the all of results with national or international studies, the 5-year survival rate in our study did not differ from the 5-year survival published from the general population.
Previous studies have shown that the survival of OC is affected by personal history, and genetic factors including low socioeconomic status, and life style. 18, [22] [23] [24] [25] [26] We scrutinized the analyzing related to various prognostic factors for OC. In the present study younger women, those diagnosed before the age of 40, had significantly better survival after five years than women diagnosed at older ages (p< 0.05). Older age at diagnosis was often associated with comorbidities and functional deficits that impact their survival. Gershenson et al 27 reported on a cohort of 112 patients with stage II-IV low-grade serous carcinoma from M.D. Anderson Cancer Center in 2006, and noted age older than 45 years at diagnosis was associated with longer survival. Some studies reported that increasing age was most strongly associated with poor survival. 9, 10, [18] [19] [20] 22 However, in the other studies of Oge et al 7 and Buldanlı et al 11 revealed that age was not was not effected by the age of the patients in OC.
Recently, treatments for cancer has resulted in increasingly complex care patterns and individualization of care by multidisciplinary teams. Lack of access to a qualified region for proper oncology center may impact outcome and contribute to disparities in early stage cancer. Access to on site appropriately qualified healthcare center is essential to decrease distance barriers and to improve survival. 22 Conversely, Shylasree et al 28 analyzed that there were no significant differences survival between women managed in the cancer center and those managed in the peripheral units. In our study, the patients are referred to the study hospital because they do not have a high-quality healthcare setting in the periphery. In our study, patients who traveled less than 50 miles for their cancer care 24 in 2012 identified five studies (total 62.987 women with gynecological cancer), and concluded that women with advanced OC may have improved outcomes if treated in specialist centers (in a twofold). In the light of this information, these results would be important for future studies to assess the survival associated with centralization of this cancer care.
Beyond some demographic and medical features, relatively little is known about reproductive factors that may influence survival after OC diagnosis. 5 In our study revealed women with postmenopausal had poorer OS scores than women with premenopausal (p< 0.05). OC may be diagnosed earlier in premenopausal women than in postmenopausal women, because one major symptom used to identify OC is a change in menstruation. Premenopausal women are also more likely to develop types of tumors that are easier to detect and therefore, the chances of survival are higher. 18, 22, 23 Our results were similar previously reported in the literature but inconsistent with a population-based cohort study of Australian women that found no association. 20 Comorbidities such as diabetes, heart disease and hypertension may impact this treatment disparity. The majority of studies show that comorbidities were found as the prognostic factors that influence the survival. 6, 18, 28, 29 In a different study 20 , a high comorbidity score of ≥2 was associated with a decreased OS rates (HR, 1.5 [95% CI, 1.1-2.1]). When we performed our analyses, we either did found a relationship, higher comorbidity score was found to have poorer OS. The results of our study are consistent with the literature.
Due to the prolonged OC course, obesity as potentially modifiable risk factors may alter the survival. Suh et al 30 reported that survival of OC was more influenced by the obese environment. In a different study 25 , obesity was found significant predictors of OS. In this study similarly, overweight/obesity defined as a BMI ≥25 kg/m 2 , demonstrated association with worse OS. The role of obesity on survival both in the literature and in our results provides evidence for women diagnosed with OC. Therefore, avoiding obesity in relation to treatment practices is the main strategy to improve the survival, as the health provider is expected to address obesity factors in developing a plan of care.
Some types of OC have a more favorable prognosis. As reported in several studies, mucinous or clear-cell histology was associated with a worse OS compared with serous carcinomas. 6, 9, 11, 18, 20 Similar to others, we found that women with clear cell, endrometrioid and mucinous type had the poorest survival, possibly reflecting aggressive tumor biology or less sensitivity to routinely used chemotherapy. However, Benvito et 23 and Shysasree et al 28 were not found of survival differences between subtypes and survival. Akhtar-Danesh et al 22 reported that the worst survival observed for serous tumors.
In our study, low-grade tumor was associated with a more favorable prognosis than high-grade (p< 0.05). Bodurka et al 31 analyzed 378 women with low-grade tumors had significantly longer median DFS values than those with high-grade carcinomas (45.0 vs 19.8 months; p< 0.001). Similarly, other studies found that higher grade remained significantly associated with survival. 6, 9, 11, 17, 18, 20, 23 A multivariate analysis showed that, for OC, the histological grade was a significant prognostic factor for DFS but not for OS. 19 As reported in several studies, grade as important prognostic factors is still controversial.
Matz et al 8 analyzed data from 60 countries for 695.932 women with OC during 2005-2009. 5-year OS ranged from 40 to 70% for type I localized epithelial OC, for type II advanced epithelial tumors was much lower (20-45%). In a different study, the survival rates were higher for women with earlier stage cancers. 9 We found that stage was the most important prognostic factor with regard to survival. Consistent with other work, we also revealed that high stage had significantly effect on OS (p< 0.05). In contrast, Shylasree et al 28 analyzed the outcomes of 250 women with OC and there were no significant differences regarding stage between OS.
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Currently, there is no recommendation for routine OC screening from any national organization. Routinely checking markers and CT scans do not result in early detection or longer survival in either the general or high-risk populations. 5 An elevated CA125 was not determinant factors of OS in our study (p> 0.05) in our study. Similar to the study of Whoo et al 24 CA125 level was not influence on OS for OC. However we found that presence of recurrence had significant effect on survival in OC (p> 0.05). As mentioned in several studies the patients with recurrent had significantly shorter survival.
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Conclusion
In the result of this study, the 5-year survival for OC was 42.8%. The time of OS for patients was 60.5 months and the median DFS rate was 18.3 months, clearly reinforcing the need for prevention, early detection and better treatments. Advanced age, subtype, recurrence, comorbidities, obesity, distance to residence, postmenopausal period, stage and grade were also associated with OS. Ideally, any prospective studies should be performed on large number of patients to accurately establish whether geographic and socioeconomic differences, and medical features relate to survival. Until better screening tools are available, patient education and close follow-up remain the most important intervention for prevention of OC. Also, individualized healthcare may be able to determinant impact on survival for these women.
Limitations
All of data from were a single hospital registry, thus not representative of the general population. However, this study was a maiden attempt to reveal that substantial prognostic factors of OC. Also, none of the studies looked at risk of some social factors such as regional distance or caregiver support, which would be important to those commissioning healthcare services.
